Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy

We report our experience with the use of intravitreal ranibizumab for the treatment of retinopathy of prematurity (ROP). A retrospective review was performed on 138 consecutive infants screened at a single centre over 18 months. Intravitreal ranibizumab was offered in selected cases requiring treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Joyce J. T., Lam, Carol P. S., Kwok, Madeline K. M., Wong, Raymond L. M., Lee, Gary K. Y., Lau, Winnie W. Y., Yam, Jason C. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891718/
https://www.ncbi.nlm.nih.gov/pubmed/27256987
http://dx.doi.org/10.1038/srep27082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891718/
https://www.ncbi.nlm.nih.gov/pubmed/27256987
http://dx.doi.org/10.1038/srep27082

Ejemplares similares